Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ)
Changsha, CN
Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that spans the entire value chain from drug discovery and development to manufacturing and commercialization. The company's extensive product line includes medications for treating allergies, infections, and inflammatory conditions, as well as analgesics and gynecological remedies. Their offerings further extend to products for digestive health, both Western chemical drugs and traditional Chinese patent medicines, medical equipment, and Active Pharmaceutical Ingredients (APIs). Additionally, Hunan Jiudian provides contract manufacturing services for various pharmaceutical formulations, such as tablets, capsules, granules, and oral liquid preparations like solutions and syrups. The company is headquartered in Changsha, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.73% | +1.56% | -8.56% | -24.10% | -26.70% | -21.56% | -26.33% | -42.99% | -22.08% | +120.45% | +120.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+6.2% ★ Q1'26: -14.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-8.7% Q1'26: -56.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+16.8% Q1'26: +3.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+18.8% ★ Q1'26: +11.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+19.6% ★ Q1'26: +9.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q1'26: +2.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.68× ★ Q1'26: 1.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
534.52M
est: 462.00M (+15.7%)
|
801.38M
est: 552.00M (+45.2%)
|
924.06M
est: 662.00M (+39.6%)
|
978.16M
est: 1.09B (-10.2%)
|
1.63B
est: 1.66B (-2.0%)
|
2.33B
est: 2.25B (+3.6%)
|
2.69B
est: 2.84B (-5.2%)
|
2.93B
est: 3.08B (-4.8%)
|
3.11B
est: 3.28B (-5.2%)
|
3.47B
3.47B – 3.47B
+5.7% YoY
|
3.81B
3.81B – 3.81B
+9.8% YoY
|
| EBITDA |
87.37M
est: 75.72M (+15.4%)
|
96.02M
est: 90.48M (+6.1%)
|
90.15M
est: 108.51M (-16.9%)
|
126.39M
est: 178.49M (-29.2%)
|
264.80M
est: 272.25M (-2.7%)
|
338.49M
est: 368.08M (-8.0%)
|
446.50M
est: 901.23M (-50.5%)
|
633.88M
est: 977.05M (-35.1%)
|
707.33M
est: 1.04B (-32.0%)
|
1.10B
1.10B – 1.10B
+5.7% YoY
|
1.21B
1.21B – 1.21B
+9.8% YoY
|
| EBIT |
71.76M
est: 60.40M (+18.8%)
|
73.58M
est: 72.17M (+2.0%)
|
52.80M
est: 86.55M (-39.0%)
|
78.16M
est: 142.37M (-45.1%)
|
211.22M
est: 217.15M (-2.7%)
|
278.84M
est: 293.58M (-5.0%)
|
375.12M
est: 766.68M (-51.1%)
|
541.62M
est: 831.18M (-34.8%)
|
583.19M
est: 885.42M (-34.1%)
|
936.16M
936.16M – 936.16M
+5.7% YoY
|
1.03B
1.03B – 1.03B
+9.8% YoY
|
| Net Income |
68.57M
est: 100.29M (-31.6%)
|
71.99M
est: 123.17M (-41.6%)
|
55.07M
est: 151.32M (-63.6%)
|
82.26M
est: 85.46M (-3.7%)
|
204.25M
est: 223.71M (-8.7%)
|
269.70M
est: 282.94M (-4.7%)
|
368.26M
est: 469.96M (-21.6%)
|
512.38M
est: 385.72M (+32.8%)
|
472.82M
est: 587.29M (-19.5%)
|
627.11M
627.11M – 627.11M
+6.8% YoY
|
726.65M
726.65M – 726.65M
+15.9% YoY
|
| SGA |
168.14M
est: 242.55M (-30.7%)
|
333.84M
est: 289.80M (+15.2%)
|
442.70M
est: 347.55M (+27.4%)
|
545.51M
est: 571.73M (-4.6%)
|
877.00M
est: 872.03M (+0.6%)
|
1.28B
est: 1.18B (+9.0%)
|
1.41B
est: 1.44B (-2.6%)
|
1.33B
est: 1.56B (-14.9%)
|
1.47B
est: 1.67B (-11.8%)
|
1.76B
1.76B – 1.76B
+5.7% YoY
|
1.93B
1.93B – 1.93B
+9.8% YoY
|
| EPS |
0.26
est: 0.20 (+27.7%)
|
0.22
est: 0.25 (-12.0%)
|
0.17
est: 0.31 (-44.7%)
|
0.25
est: 0.17 (+44.1%)
|
0.62
est: 0.45 (+36.5%)
|
0.69
est: 0.57 (+20.1%)
|
0.77
est: 0.94 (-18.5%)
|
1.05
est: 0.78 (+35.5%)
|
0.96
est: 1.18 (-18.6%)
|
1.26
1.26 – 1.26
+6.8% YoY
|
1.46
1.46 – 1.46
+15.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 52.3K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 212.0K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 129.2K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 89.5K | 0.29% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 12.1K | 0.46% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.5K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 16.8K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 829.4K | 0.06% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 50.6K | 0.28% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 11.1K | 0.10% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guo Wang | Accounting Supervisor | — | — |
| Lei Zeng | Deputy GM & Secretary of the Board | — | female |
| Pengyun Fan | Deputy GM & Director | — | male |
| Yang Yang | Non-Independent Director & GM | — | male |
| Ying Liu | Deputy General Manager | — | male |
| Ying Xiong | Financial Director | — | female |
| Zhi Yun Zhu | Director of Supply & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300705.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
